TABLE 2.

Median Survival After Single-ICI, Dual-ICI, TRT, or TRT + Dual-ICI

	Single-ICI			Dual-ICI			TRT + dual-ICI
Control	Anti-CTLA-4	Anti-PD-L1	Anti-PD-1	Anti-PD-L1 + anti-CTLA-4	Anti-PD-1 + anti-CTLA-4	TRT (177Lu-LLP2A)	TRT + anti-CTLA-4 + anti-PD-L1	TRT + anti-CTLA-4 + anti-PD-1
14 d	15.5 d	15.5 d	15.5 d	18 d	17.5 d	19 d	23 d	22 d

All treatment groups were significantly better than control (P < 0.005). No ICI groups significantly differed except anti-PD-L1 vs. anti-PD-L1 + anti-CTLA-4 (P = 0.0082). TRT + dual-ICI was significantly better than TRT alone (P < 0.001) or dual-ICI (P < 0.0005).